CD274 and non-small cell lung carcinoma: The potential predictive value of PD-L1 by RNA-seq for pembrolizumab monotherapy response, progression-free survival (PFS), and overall survival (OS) was explored using the 75th percentile rank cutoff in a cohort of NSCLC patients who received pembrolizumab monotherapy as their first immunotherapy following testing (n = 102) (Table 1).